207 related articles for article (PubMed ID: 11264164)
1. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.
Kano Y; Akutsu M; Tsunoda S; Mano H; Sato Y; Honma Y; Furukawa Y
Blood; 2001 Apr; 97(7):1999-2007. PubMed ID: 11264164
[TBL] [Abstract][Full Text] [Related]
2. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
Cancer; 2002 May; 94(10):2653-62. PubMed ID: 12173333
[TBL] [Abstract][Full Text] [Related]
3. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.
Topaly J; Zeller WJ; Fruehauf S
Leukemia; 2001 Mar; 15(3):342-7. PubMed ID: 11237055
[TBL] [Abstract][Full Text] [Related]
4. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.
Sun X; Layton JE; Elefanty A; Lieschke GJ
Blood; 2001 Apr; 97(7):2008-15. PubMed ID: 11264165
[TBL] [Abstract][Full Text] [Related]
5. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.
Mow BM; Chandra J; Svingen PA; Hallgren CG; Weisberg E; Kottke TJ; Narayanan VL; Litzow MR; Griffin JD; Sausville EA; Tefferi A; Kaufmann SH
Blood; 2002 Jan; 99(2):664-71. PubMed ID: 11781252
[TBL] [Abstract][Full Text] [Related]
6. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.
Klejman A; Rushen L; Morrione A; Slupianek A; Skorski T
Oncogene; 2002 Aug; 21(38):5868-76. PubMed ID: 12185586
[TBL] [Abstract][Full Text] [Related]
7. The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents.
Liu WM; Stimson LA; Joel SP
Br J Cancer; 2002 May; 86(9):1472-8. PubMed ID: 11986783
[TBL] [Abstract][Full Text] [Related]
8. ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis.
Nakajima A; Tauchi T; Ohyashiki K
Leukemia; 2001 Jun; 15(6):989-90. PubMed ID: 11417489
[No Abstract] [Full Text] [Related]
9. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.
Thiesing JT; Ohno-Jones S; Kolibaba KS; Druker BJ
Blood; 2000 Nov; 96(9):3195-9. PubMed ID: 11050003
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.
Kano Y; Akutsu M; Tsunoda S; Izumi T; Kobayashi H; Mano H; Furukawa Y
Invest New Drugs; 2007 Feb; 25(1):31-40. PubMed ID: 16865529
[TBL] [Abstract][Full Text] [Related]
11. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.
Parmar S; Katsoulidis E; Verma A; Li Y; Sassano A; Lal L; Majchrzak B; Ravandi F; Tallman MS; Fish EN; Platanias LC
J Biol Chem; 2004 Jun; 279(24):25345-52. PubMed ID: 15056660
[TBL] [Abstract][Full Text] [Related]
12. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
O'Hare T; Eide CA; Deininger MW
Expert Opin Investig Drugs; 2008 Jun; 17(6):865-78. PubMed ID: 18491988
[TBL] [Abstract][Full Text] [Related]
13. In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
Kano Y; Akutsu M; Tsunoda S; Suzuki K; Ichikawa A; Furukawa Y; Bai L; Kon K
Leukemia; 2000 Mar; 14(3):379-88. PubMed ID: 10720130
[TBL] [Abstract][Full Text] [Related]
14. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.
Gambacorti-Passerini C; Barni R; le Coutre P; Zucchetti M; Cabrita G; Cleris L; Rossi F; Gianazza E; Brueggen J; Cozens R; Pioltelli P; Pogliani E; Corneo G; Formelli F; D'Incalci M
J Natl Cancer Inst; 2000 Oct; 92(20):1641-50. PubMed ID: 11036109
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J
Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976
[TBL] [Abstract][Full Text] [Related]
16. The influence of imatinib mesylate (STI571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro.
Korycka A; Robak T
Leuk Lymphoma; 2003 Sep; 44(9):1549-55. PubMed ID: 14565659
[TBL] [Abstract][Full Text] [Related]
17. Apoptotic synergism between STI571 and the farnesyl transferase inhibitor SCH66336 on an imatinib-sensitive cell line.
Brodsky AL
Blood; 2003 Mar; 101(5):2070; author reply 2070-1. PubMed ID: 12584143
[No Abstract] [Full Text] [Related]
18. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.
La Rosée P; Johnson K; O'Dwyer ME; Druker BJ
Exp Hematol; 2002 Jul; 30(7):729-37. PubMed ID: 12135670
[TBL] [Abstract][Full Text] [Related]
19. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA; Laug WE; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
[TBL] [Abstract][Full Text] [Related]
20. TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells.
Uno K; Inukai T; Kayagaki N; Goi K; Sato H; Nemoto A; Takahashi K; Kagami K; Yamaguchi N; Yagita H; Okumura K; Koyama-Okazaki T; Suzuki T; Sugita K; Nakazawa S
Blood; 2003 May; 101(9):3658-67. PubMed ID: 12506034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
